Bodywell Ayurveda Earns Global Recognition Through Regulatory Compliance and Strategic Expansion

IMT News Desk
IMT News Desk
· 3 min read
Indian Ayurvedic brand builds success through regulatory compliance.

Homegrown Ayurvedic brand Bodywell Ayurveda is announcing a series of milestones that position it as a regulatory-compliant player on the global wellness stage, built on years of operating within India’s stringent regulatory framework.

The company, which holds valid Ayurveda and food manufacturing licences in full compliance with national regulatory standards, is now stocked in over 2,000 Apollo Pharmacy stores, available at more than 40 airport retail outlets, and has completed product registrations in the 20 most prominent European Union markets.

Foundation Built on Regulatory Compliance

“There is a particular kind of confidence that only comes from doing things the right way, even when no one is watching,” the company stated. For Bodywell Ayurveda, that confidence has been built over years of obtaining necessary licences and refusing to cut corners in a market where it would have been easy to do so.

The brand holds valid Ayurveda and food manufacturing licences in full compliance with national regulatory standards, ensuring products are not just marketed well but manufactured according to established protocols.

Mainstream Retail Presence Through Apollo Pharmacies

Getting products onto Apollo Pharmacy shelves requires surviving a level of scrutiny that many smaller brands cannot meet. Bodywell Ayurveda is now available across more than 2,000 Apollo stores nationwide, giving customers in Mumbai, Lucknow, Coimbatore, or Bhubaneswar access to the brand alongside established pharmaceutical products.

This mainstream accessibility represents a genuine shift in how traditional wellness is being integrated into modern healthcare retail in India.

Airport Retail Expansion

Bodywell Ayurveda products are now available at more than 40 national and international airport stores across India. For a health brand, this channel is particularly valuable because airport wellness shoppers typically have disposable income, health awareness, and curiosity to try new products.

For international travelers, picking up an Ayurvedic supplement from a recognized, licensed Indian brand is compelling. For Indian travelers heading abroad, it’s a chance to carry something they trust.

European Union Market Clearance

The European Union maintains some of the world’s most demanding regulations around product safety, ingredient transparency, manufacturing documentation, labeling compliance, and substantiation of health claims. Countries like Germany, France, Sweden, and the Netherlands have regulatory bodies that rigorously review submissions.

Bodywell Ayurveda has completed product registrations in the top 20 EU countries, clearing regulatory hurdles across markets with different languages, regulatory nuances, and consumer expectations. This validation confirms that the brand’s quality systems, ingredient sourcing, and manufacturing practices meet international benchmarks.

Strategic Positioning

“We never set out to be the loudest Ayurvedic brand in the room. We set out to be the one that could walk into any boardroom, any pharmacy chain, any regulatory office in the world and answer every question with complete confidence,” a company spokesperson stated.

The brand is committed to bringing authentic Ayurvedic formulations to consumers who expect both tradition and transparency.

The expansion comes as India’s AYUSH sector gains global attention, with the 9th Ayurveda Day theme announced as “Ayurveda Innovation for Global Health”.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk